Business News • PR NewsWire • Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA

Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA

Regeneron and Sanofi Announce Dupilumab Biologics License Application Accepted for Priority Review by U.S. FDA

TARRYTOWN, N.Y. and PARIS, Sept. 26, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for dupilumab for the...

View More : http://www.prnewswire.com/news-releases/regeneron-and-sanofi-announce-dupilumab-biologics-license-application-accepted-f...

Releted News by prnewswire